Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results

On June 13, 2019 Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA,OTCQB: MDNAF), a clinical stage Immuno-Oncology company, reported that it will host a Key Opinion Leader call and webcast for the investment community on Tuesday, June 18, 2019 at 1 PM, EDT (Press release, Medicenna Therapeutics, JUN 13, 2019, View Source [SID1234537071]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will be focused on Medicenna’s MDNA55 recurrent glioblastoma (rGBM) program which recently completed enrolment and will discuss preliminary top-line tumor response results to be presented at the Inaugural Immuno-Oncology Pharma Congress held on June 18, 2019 during World Pharma Week in Boston, MA.

Featured Speakers:

John H. Sampson, MD, PhD, Robert H. and Gloria Wilkins Distinguished Professor and Chair of Neurosurgery at Duke University in Durham, NC
Dr. Sampson leads an active research laboratory investigating new modalities of brain tumor infusion using Convection Enhanced Delivery (CED) and immunotherapy and is internationally recognized in the field of neurosurgery, neuro-oncology and immunotherapy. In addition, he has special training in the design and conduct of clinical trials. Dr. Sampson earned his medical degree from the University of Manitoba in Winnipeg, Canada and a PhD in neuro- immunology and brain tumor immunotherapy at Duke University. He completed his MBA at the Fuqua School of Business. He has authored more than 240 peer-reviewed publications in this field and has been continuously funded by the NIH since 2000.

Martin Bexon, MD, Head of Clinical Development at Medicenna
Dr. Bexon, has extensive experience in early and late stage clinical development including medical affairs particularly in oncology and hematology. While at CSL Behring he led multiple global clinical studies and as Global Medical Director, he led their medical affairs function. At Hoffman-La Roche Dr. Bexon designed and implemented multiple global clinical trials enrolling more than 10,000 subjects. He has also led teams filing numerous regulatory submissions on both sides of the Atlantic and Japan. Prior to joining pharma, he practiced in the clinic as a pediatrician.

Conference call and webcast details:
Date: June 18, 2019
Time: 1:00 pm EDT

To access the conference audio:
Local dial in: 416-764-8609
North American Toll Free: 1-888-390-0605
Conference ID No.: 65571448

To access the webcast and slide presentation:

View Source

Following the event, the archived webcast and Medicenna presentation will be available on the Company’s website at www.medicenna.com. The webcast will be archived for 30 days after the event.

IMV Inc. to Present at Two Upcoming Investor Conferences

On June 13, 2019 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, reported that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in June (Press release, IMV, JUN 13, 2019, View Source [SID1234537070]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Raymond James Life Sciences and MedTech Conference

Date: Wednesday, June 19, 2019
Time: 4:10 p.m. ET
Format: Presentation and webcast
Location: Lotte New York Palace, New York, NY
The Oppenheimer Summit for Emerging Biotechnology

Date: Wednesday, June 26, 2019 to Friday, June 28, 2019
Format: Attendance and one-on-one presentations
Location: Gurney’s Star Island Resort and Marina, Montauk, NY
A copy of each the investor presentations will be available in the events and presentations section of IMV’s website. Also, a live webcast of IMV’s presentation at the Raymond James Life Sciences and MedTech Conference will be available and archived for 90 days on the events and presentations webpage.

Servier announces European Commission decision to convert conditional approval into standard marketing authorization in patients with aggressive non-Hodgkin B-cell lymphoma for PIXUVRI® (pixantrone)

On June 13, 2019 Servier reported that the European Commission (EC) has approved the conversion of the conditional approval of PIXUVRI (pixantrone) into a standard marketing authorization as a single agent for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma (Press release, Servier, JUN 13, 2019, https://www.businesswire.com/news/home/20190613005025/en/Servier-announces-European-Commission-decision-convert-conditional [SID1234537069]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"There are limited treatment options for multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma," said Prof Pier Luigi Zinzani from the University of Bologna Institute of Hematology and Medical Oncology in Bologna, Italy. "PIXUVRI has demonstrated efficacy in late stage disease and the EC approval confirms PIXUVRI as a treatment option for these patients."

The EC approval is based on data from the global clinical development of PIXUVRI.

The pivotal study, PIX301 was an open-label, randomized, Phase III study comparing PIXUVRI monotherapy with physician’s choice of treatment in 140 patients with relapsed or refractory aggressive non-Hodgkin lymphoma, 50% of whom had been previously treated with rituximab. PIXUVRI was shown to be beneficial in these patients: 20% of patients responded completely to PIXUVRI compared with 5.7% of patients receiving other agents (p=0.021).1,2

To satisfy requirements of the conditional authorization, a further Phase III clinical study, PIX306, was completed to provide additional efficacy data to confirm the benefit of PIXUVRI in patients that had received prior treatment regimens containing rituximab. In the study PIX306, all patients were previously treated with rituximab. While the superiority of PIXUVRI with rituximab compared to gemcitabine with rituximab was not met, both progression-free survival and overall survival results in patients with ≥ 2 prior treatment lines were similar, when indirectly compared to the PIXUVRI treated population in the pivotal study PIX301.2,3

"At Servier, we work diligently to develop and deliver medicines that address critical unmet medical needs in diseases such as multiply relapsed or refractory aggressive non-Hodgkin lymphoma," said Patrick Therasse, Head of Servier Research and Development Oncology. "PIXUVRI has been benefitting patients since its conditional approval in 2012 but today’s decision brings reassurance to patients and clinicians that this medicine remains a relevant treatment option in this indication."

The most common side effects with PIXUVRI are neutropenia, leukopenia, lymphopenia, anemia, thrombocytopenia, nausea, vomiting, skin discolouration, alopecia, chromaturia and asthenia.1

#ENDS#

About non-Hodgkin lymphoma (NHL)

NHL is a blood cancer that affects the lymphatic system, which is defined as a network of vessels and glands that run throughout the body.4 The lymphatic system is a key component of the immune system, as it plays a role in destroying old or abnormal cells and fighting bacteria and other infections.5

NHL can occur in different parts of the body from the lymph nodes in the neck to the liver or spleen, but also in other organs such as the stomach, small bowel, bones, brain, testicles or skin.6 Around 168,000 new cases of NHL are diagnosed in the United States and Europe every year.

About PIXUVRI (pixantrone)

PIXUVRI is indicated in the European Union as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma.7 PIXUVRI is a cytotoxic medicine that works by interfering with the DNA within cells and preventing them from making more copies of DNA. This means that the cancer cells cannot divide and eventually die.8

PIXUVRI is mentioned in the ESMO (Free ESMO Whitepaper) guidelines as an anthracycline-like drug with reduced cardiotoxicity, which demonstrated some efficacy in heavily treated patients.9

More detail is available in the summary of the European public assessment report (EPAR) on the EMA website at www.ema.europa.eu.

Servier commercializes PIXUVRI under a license from CTI BioPharma.

Intrexon’s Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference

On June 13, 2019 Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its wholly-owned Intrexon Health subsidiary Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, reported their presentation at the JMP Securities Life Sciences Conference in New York. Helen Sabzevari, PhD, President of Precigen, will highlight Intrexon Health and Precigen in the presentation on Thursday, June 20, 2019 at 12:30 pm Eastern Time (Press release, Intrexon, JUN 13, 2019, View Source [SID1234537068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investors section of Intrexon’s website under ‘Events’ at investors.dna.com/events and on Precigen’s website under ‘Presentations’ at www.precigen.com/media/#id-presentations. The presentation will be archived on the Intrexon and Precigen websites for 30 days following the event.

BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference

On June 13, 2019 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, reported that its Chief Executive Officer, Philip Serlin, will present a company update at the JMP Securities 2019 Life Sciences Conference on Wednesday, June 19, 2019 at 2:00 p.m. (EDT) (Press release, BioLineRx, JUN 13, 2019, View Source [SID1234537067]). The conference will be held at the St. Regis New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on BioLineRx’s website. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.